Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

September 2010 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Allergen Epitope Validation Resource

For the published request for applications, see the April 7, 2011, Guide announcement, Allergen Epitope Research and Validation Centers.

Cooperative Study Group for Autoimmune Disease Prevention

For the published request for applications, see the June 17, 2011, Guide announcement.

Stem Cell Transplantation for the Treatment of Scleroderma

Request for Proposals - JOFOC

Contact: Donald Collie

Objective: To continue support for the existing contract to complete the ongoing clinical trial evaluating the safety, toxicity, and efficacy of stem cell transplantation for the treatment of scleroderma and the mechanism underlying this intervention.

Description: An ongoing study called: "Randomized Open-label, Phase II Multi-Center Study of High Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+ HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis" (short name: Scleroderma: Cyclophosphamide or Transplantation [SCOT]).

Last Updated July 08, 2011

Last Reviewed June 20, 2011